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Epilepsy is a serious neurological condition and pharmacotherapy is not effective for all
patients and causes serious adverse effects and pharmacokinetic and pharmacodynamic
interactions. Natural products and ethnobotanical resources can help develop new
therapeutic options for conditions like epilepsy. In Puerto Rico, ethnobotanical resources
highlight the anxiolytic properties of a tea like preparation made from the leaves of the
Citrus aurantium tree or bitter orange. Studies performed with essential oils from the
peel of the fruit have shown to increase seizure latency to pentylenetetrazole (PTZ) and
maximal electroshock seizure in mice. We characterized the extract composition, and used
a model of PTZ induces seizures in the zebrafish and a receptor-ligand binding assay to
determine if this preparation has anticonvulsant properties and its mechanism of action.
We determined that the aqueous extract made from the leaves of the C. aurantium
tree contains hesperidin, neohesperidin, and neohesperidin dihydrochalcone. Using our
zebrafish model, we determined that exposure to the C. aurantium 28mg/mL extract in
aquarium water increases seizure latency by 119% compared to controls. We ruled out a
mechanism involving GABAA receptors using the selective antagonist gabazine. We used
two approaches to study the role of glutamate in the mechanism of the C. aurantium
extract. The ligand binding assay revealed C. aurantium extracts at concentrations of
0.42 to 5.6mg/mL significantly reduced [3H]Glu binding indicating an interaction with
glutamate receptors, in particular with NMDA receptors and mGluR II. This interaction was
confirmed with our animal model using selective receptor antagonists and we identified
an interaction with mGluR I, not observed in the ligand binding experiment. These study
provide evidence of the anticonvulsant properties of the aqueous extract made from the
leaves of the C. aurantium tree and a mechanism involving NMDA and mGluR’s I and II.
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INTRODUCTION
Epilepsy affects 50 million people worldwide (Meyer et al., 2010).
It is a disorder of brain function characterized by the periodic
and unpredictable occurrence of seizures caused by abnormal
Abbreviations: CA, Citrus aurantium; [3H]Glu, [3H]Glutamate; AMPA,
Alpha-amino-3-hydroxy-5-methylisox-azole-4-propionic acid; BSA, Bovine
serum albumin; CPPG, (RS)-α-Cyclopropyl-4-phosphonophenylglycine;
DCG-IV, (2S,2′3R,3′R)-2-(2′,3′-Dicarboxycyclopropyl)glycine; EGLU,(2S)-
a-Ethylglutamic acid; FW, Fluorowillardiine; iGluR, Ionotropic glutamte
receptor; KA, Kainic acid; L-AP4, L-(+)-2-Amino-4-phosphonobutyric acid;
LCCG-I, (2S,1′S,2′S)-2-(Carboxycyclopropyl)glycine; mGluR I, Group I of the
metabotropic glutamate receptor (1,5); mGluR II, Group II of the metabotropic
glutamate receptors (2,3); mGluR III, Group III of the metabotropic glutamate
receptors (4,6,7,8); NMDA, N-methyl-D-aspartic acid; PHCCC, N-Phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide; PTZ, Pentylenetetrazole;
QA, quisqualic acid: (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)
propanoic acid); D-AP5, D-(-)-2-Amino-5-phosphonopentanoic acid; NBQX,
2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide; UBP
301, (αS)-α-Amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-5-iodo-2,4-dioxo-
1(2H)-pyrimidinepropanoic acid; ACN, Acetonitrile; MeOH, Methanol; GBZ,
gabazine.
neuronal firing. It is a lifelong condition that requires contin-
uous use of antiepileptic drugs (AED’s) but the ones clinically
available are not effective in all patients and, because of repeated
use, patients develop tolerance to their medication (Löscher and
Schmidt, 2006). In addition, AED’s have serious adverse effects
including sedation and drowsiness, cognitive impairment, hir-
sutism, weight gain (Cramer et al., 2010), and complex pharma-
cokinetic and pharmacodynamic interactions with an extensive
number of commonly used medications (Patsalos and Perucca,
2003). These issues highlight the need for new and better thera-
peutic agents to replace current available options or to improve
their effects. This can be achieved using natural products and
ethnobotanical resources to identify possible candidates for drug
development.
Ethnobotanical resources from Puerto Rico document the use
of a tea made from the leaves of the Citrus aurantium tree as
an anxiolytic remedy (Hernández et al., 1984; Alvarado-Guzmán
et al., 2009) although there are is no scientific evidence docu-
menting these properties. In experimental models of epilepsy, the
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essential oils from the peel of the fruit were able to increases
seizure latency to pentylenetetrazole (PTZ) and maximal elec-
troshock seizure in mice (Carvalho-Freitas and Costa, 2002).
These essential oils also reduce anxiety like behavior in mice
(Pultrini et al., 2006). Since the essential oils of the peel have anti-
convulsant properties, it is important to determine if the aqueous
extract made from the leaves of the C. aurantium tree also possess
anticonvulsant properties.
Natural products are a valuable source of possible therapeutic
agents since they tend to have fewer side effects than conven-
tional therapeutic agents (Reeta et al., 2011). Also, extracts from
natural products can be refined and modified to take advantage
of their properties and develop therapeutic options. Identifying
natural products with anticonvulsant properties could lead—in
the future—to the development of new therapeutic options (Dias
et al., 2012; Lahlou, 2013). Using amodel of PTZ induced seizures
in zebrafish, we documented the anticonvulsant properties of this
aqueous extract and established a possible mechanism involv-
ing NMDA and mGluR’s I and II. To our knowledge, this is the
first time and aqueous extract made from the leaves of the C.
aurantium tree has been studied, giving insight to the pharma-
cological properties of a preparation commonly used by patients,
particularly in Puerto Rico. This work supports the value of eth-
nobotanical resources and folk medicine during the identification
of new therapeutic compounds.
MATERIALS AND METHODS
ANIMAL HUSBANDRY
Adult wild type zebrafish (Danio rerio), 3–6 month-old male and
female and approximately 0.25 ± 0.04 g in weight were obtained
from a local commercial distributor (Caribe Fisheries, Inc., Lajas,
PR). Animals were housed in acrylic tanks covered with blue con-
tact paper to reduce stress caused by traffic in the laboratory
room dedicated as satellite facility for housing. Animals are kept
at a density of approximately 5 animals per liter of water. These
tanks were maintained with deionized tap water, supplemented
with 60mg/L Instant Ocean® Sea Salt (Spectrum) to achieve
the appropriate water chemistry (Reed and Jennings, 2011). Fish
tanks were maintained with constant filtration systems (mechan-
ical and biological). The water temperatures were maintained
at 25–27◦C using water heaters. Illumination was provided by
ceiling-mounted fluorescent light tubes on a 14 h light/10 h dark
cycle. Fish were allowed a week in quarantine to acclimate to
their new environment and determine health condition before
any experiment was performed. Animals were hand fed at least
once a day and fed by an automatic dispenser twice a day with
Tetramin® tropical fish flake food (Tetra Co.) or Wardley trop-
ical fish flake food depending on availability. All experimental
manipulations were performed between 8 a.m. and 5 p.m. in a
designated bench on the main laboratory room.
These experiments were performed in accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory
Animals of the National Research Council (US) Committee for
the Update of the Guide for the Care and Use of Laboratory
Animals to minimize pain and distress to the animals. The
Protocol was approved by the Institutional Animal Care and Use
Committee of the University of Puerto Rico, Medical Sciences
Campus (Protocol 3180110). An n = 10–15 animals per variable
was selected as this range proves enough to establish statisti-
cally valid difference between control and experimental groups
(Wong et al., 2010). Animals showing signs of distress either in the
housing tanks or during experiments were humanely euthanized
following institutional IACUC regulations.
CHEMICALS
L-[2,3,4-3H]-Glutamic acid ([3H]Glu) (60 Ci/mmol) and was
obtained from American Radiolabeled Chemicals, Inc. (St.
Louis, MO). N-Methyl-D-aspartic acid (NMDA, 99% purity,
105mM in Tris-HCl buffer pH 7.4), kainic acid (KA, 98% purity,
10mM stock in Tris-HCl buffer pH 7.4), Fluorowiillardiine
(FW, 98% purity, 10mM stock in Tris-HCl buffer pH 7.4),
(L)-(+)-α-Amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic
acid (QA, 99% purity, 10mM stock in Tris-HCl buffer pH
7.4), (2S,1′S,2′S)-2-(Carboxycyclopropyl)glycine (LCCG-I,
99% purity, 100mM stock in in Tris-HCl buffer pH 7.4),
(DCG-IV, 98% purity, 100mM stock in Tris-HCl buffer pH
7.4), L-(+)-2-Amino-4-phosphonobutyric acid (L-AP4, 99%
purity, 100mM stock in Tris-HCl buffer pH 7.4), N-Phenyl-
7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide
(PHCCC, 98% purity, 4mM in 40% Tris buffer/60% DMSO)
(2S)-a-Ethylglutamic acid (EGLU, 95% purity, 100mM in 1M
NaOH), (RS)-α-Cyclopropyl-4-phosphonophenylglycine (CPPG,
98% purity, 25mM stock in DMSO), 2,3-Dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f] quinoxaline-7-sulfonamide disodium salt
(NBQX, 98% purity, 100mM stock in dH2O), D-(-)-2-Amino-
5-phosphonopentanoic acid (D-AP5, 99% purity, 100mM stock
in dH2O), (αS)-α-Amino-3-[(4-carboxyphenyl)methyl]-3,4-
dihydro-5-iodo-2,4-dioxo-1(2H)-pyrimidinepropanoic acid
(UBP 301, 98% purity 5mM stock in DMSO), 2-(3-
Carboxypropyl)-3-amino-6-(4 methoxyphenyl)pyridazinium
bromide (gabazine, 98% purity, 10mM in dH2O) were obtained
from Tocris Bioscience or Abcam. Potassium Chloride was
purchased from Matheson Coleman & Bell (Norwood, OH).
UniverSol ES was obtained from MP Biomedicals (Solon, OH).
Pentylenetetrazole (PTZ, 99% purity, 4M stock in dH2O) and all
other reagents were obtained from Sigma-Aldrich.
PREPARATION OF THE C. AURANTIUM EXTRACT
C. aurantium leaves were obtained from local trees in the Eastern
and Northern Region of the island of Puerto Rico. The leaves were
gently cleaned using a moist paper towel to remove dust and dirt
prior extract preparation and heated in ultrapure water at 32◦C
for 1 h to obtain an aqueous extract that was filtered through a
12.5 cmWhatmanQualitative no. 1 filter. Supplementary Figure 3
shows a representative photo of the leaves used. A voucher spec-
imen was deposited at the herbarium of the Botanical Garden of
the University of Puerto Rico. Voucher number is pending to be
assigned.
CHEMICAL ANALYSIS OF THE C. AURANTIUM EXTRACT
Chemical characterization of the C. aurantium extract was per-
formed by ChromaDex Inc. Briefly, the extract was prepared as
described above and stored at −80◦C for approximately 5 h and
shipped overnight to the ChromaDex facilities. According to the
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results report, for all the analysis, the sample was prepared by
filtering neat through a 0.45μM PTFE filter into a gas chro-
matography (GC) or high performance liquid chromatography
(HPLC) vial for analysis. For the limonene analysis, separation
was achieved using a HP7890 GC Series II Plus with an FID
detector. The sample was eluted with helium gas and separated
using a 2B-50 column (30.0m × 0.25mm × 0.25μm) and an
injection volume of 1μL. For the flavonoid analysis, separation
was achieved using a Agilent 110 series HPLC system with UV-
Vis detection with a Phenomenex Luna C18(2) 250 × 4.6mm,
5μm column operated at 40◦C, a gradient elution with two
mobile phases, mobile phase A: 10mM Ammonium Acetate pH
5.0, mobile phase B: 9:1 Acetonitrile(ACN):Methanol(MeOH), a
flow rate of 1.5mL/min and an injection volume of 10μL. For
the synephrine alkaloids and related amines, besides the direct
sample, a 10× dilution was also prepared by diluting the neat
with half volume 0.1% phosphoric acid in water and half volume
20mM borate buffer and filtered as described into the sample
vials. Separation was achieved using a Agilent 1100 Series HPLC
systemwith UV-Vis detection, a Phenomenex Luna C18(2) 250 ×
4.6mm, 5μm column operated at 35◦C, a gradient elution with
two mobile phases, mobile phase A: 10mM HAS in borate buffer
and mobile phase B in 20:80//CAN-Borate and 10mM HSA, a
flow rate of 0.850mL/min and injection volume of 20μL.
CEREBRAL CORTEX SYNAPTIC MEMBRANES
Synaptic membranes were prepared by Analytical Biological
Services, Inc. (Wilmington, DE) as follows: female rats of approx-
imately 2 months of age were decapitated and the brain promptly
removed. The cortex was dissected and homogenized (1:10 w/v)
in ice-cold 10mM Tris-HCl buffer pH 7.4. The homogenate
was centrifuged twice at 2500 g for 10min. The resulting super-
natant was centrifuged at 12,500 g for 20min. The pellet was
washed twice with ice-cold 10mM Tris-HCl buffer pH 7.4 (1:10
w/v) and centrifuged at 12,500 g for 20min. The pellet (synap-
tic membrane, P2) was resuspended in 10mM Tris-HCl buffer
pH 7.4 and freeze-thawed at least three times before been stored
at−80◦C until used. Protein concentration was determined using
the Bradford assay (Bradford, 1976) using bovine serum albumin
(BSA) as reference standard.
[3H]GLUTAMATE ([3H]Glu) BINDING
Receptor binding competition assays were performed using rat
cortical membranes obtained from Analytical Biological Services,
Inc. (Wilmington, DE). The reaction was initiated by adding
100μg of protein to reaction tubes containing 1mM of NMDA,
KA, and FW for ionotropic glutamate receptors (iGluR) and QA,
LCCG-H, DCG-IV, L-AP4 for metabotropic glutamate recep-
tors (mGluR) and 20 nM [3H]Glutamate in a final volume of
500μL of 50mM Tris HCl/100mM KCl buffer, pH 7.4. Non-
specific binding was determined with the presence of 1mM
non-radioactive glutamate. Total binding was determined in the
presence of various concentrations of C. aurantium extracts for
the receptor competition studies. All samples were incubated on
ice for 40min. The assay was stopped by centrifugation at 6700 g
for 30min at 4◦C. The supernatant was removed and pellets
were washed twice with 1mL of ice cold buffer. The pellet was
resuspended in 500μL of buffer. Radioactivity of the samples was
quantified in a Beckman LS 6000 counter with 5ml of EcoLume
scintillation fluid. Results are shown as percentage of total binding
(AVG ± SEM) (Del Valle-Mojica et al., 2011).
C. AURANTIUM DOSE RESPONSE CURVE
Randomly selected untreated zebrafish were placed in a small
chamber (2 cm × 2 cm × 1 cm, length × width × depth) con-
taining 15mL of a solution of the corresponding C. aurantium
extract concentration prepared in aquarium water for 1 h. After
this, animals were transferred to a clear tank (7.5 cm × 4.5 cm ×
6.0 cm, length × width × depth) with a final volume of 100mL
of PTZ (3mg/mL) prepared in aquarium water by diluting from a
4M stock solution prepared in deionized water. The time elapsed
between exposure to PTZ and loss of coordination and swimming
axis after wild jump is considered the seizure latency. Changes in
seizure latency caused by the C. aurantium extract were measured
to determine the effectiveness of the extract. Experiments were
recorded using an Olympus FE340 camera.
IN VIVO EXTRACT-RECEPTOR INTERACTION EXPERIMENTS
Randomly selected untreated zebrafish were placed for 1 h in
a small chamber (2 cm × 2 cm × 1 cm, length × width ×
depth) containing 15mL of a solution of the corresponding to
the desired concentration of the antagonists: PHCC (mGluR I),
EGLU (mGluR II) or CPPG (mGluR III), NBQX (AMPAR),
D-AP5 (NMDAR), UBP 301(KAR), and gabazine (GABAAR) pre-
pared in aquarium water. Stock solutions of PHCC, EGLU or
CPPG, NBQX, D-AP5, and gabazine where prepared in deionized
water, UBP 301 stock was prepared in DMSO. For compounds
prepared in DMSO, we performed vehicle controls with the cor-
respondent DMSO present as in the antagonist solution. After
this, animals were transferred to another small chamber contain-
ing 15mL of a solution of the C. aurantium extract prepared in
aquarium water for 1 h and then moved to a clear tank (7.5 cm ×
4.5 cm × 6.0 cm, length × width × depth) with a final volume of
100mL with PTZ (3mg/mL) to induce seizures. Control animals
for the antagonists and vehicle controls were transferred from
the solution containing the antagonist or vehicle directly into
the PTZ. Changes in seizure latency between “Antagonist” and
“Antagonist + CA” treated animals were measured to determine
possible interactions between the extract and these receptors.
Experiments were recorded using an Olympus FE340 camera.
STATISTICAL ANALYSIS
Data was normalized by the control mean and expressed as mean
values ± standard error of the mean (SEM) of at least three
independent experiments. Difference between the experimental
groups was tested for significance using One-Way analysis of vari-
ance (ANOVA) followed by the Tukey multiple comparisons test,
with p < 0.05 calculated using the GraphPad Prism software.
RESULTS
CHEMICAL ANALYSIS OF THE C. AURANTIUM EXTRACT
C. aurantium extract was tested for limonene, various flavonoids,
and synephrine and related amines. We selected these compounds
based on literature describing the characterization of various
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parts of the plant, characterization of extracts from different
extraction methods and the methods and standards available
from ChromaDex, Inc. (Castillo et al., 1992; Fugh-Berman and
Myers, 2004; Karimi et al., 2012). Table 1 shows the chemi-
cal analysis revealed the extract contained 0.107mg/mL of hes-
peridin, 0.0115mg/mL of neohesperidin, and 0.00125mg/mL
neohesperidin dihydrochalcone, trace amounts of nobiletin,
rutin, naringin, and individual citrus bioflavonoids although total
bioflavonoid concentration was determined at 0.0235mg/mL.
Limonene, naringenin, and hesperetin were not detected in the
extract.
C. AURANTIUM EXTRACTS INCREASES SEIZURE LATENCY IN
ZEBRAFISH
Animals were challenged with PTZ following exposure to C.
aurantium to measure changes on seizure latency. Figure 1
shows the effect of C. aurantium extracts in seizure latency
was dose dependent. C. aurantium extracts at high concentra-
tion significantly increased seizure latency to PTZ. C. aurantium
56mg/mL increased seizure latency to 246.9% ± 19.7, C. auran-
tium 35mg/mL to 262.8% ± 41, C. aurantium 28mg/mL to
219.4% ± 13, C. aurantium 20mg/mL to 161.2% ± 12, and
C. aurantium 14mg/mL to 138% ± 9.9 respective to untreated
animals. At lower concentrations, 0.5 and 1mg/mL, C. auran-
tium extracts showed a tendency to reduce seizure latency to PTZ
Table 1 | Chemical characterization of the C. aurantium extract.
Compound Reporting Quantity
limit (mg/ml) detected (mg/ml)
Limonene 0.019 ND
TOTAL citrus bioflavonoids Not specified 0.0235
Rutin 0.0012 BRL
Naringin 0.00097 BRL
Naringenin 0.00036 ND
Hesperidin Not specified 0.107
Neohesperidin 0.0019 0.0115
Neohesperidin dihydrochalcone 0.00043 0.00125
Hesperetin 0.00036 ND
Nobiletin 0.0049 BRL
Synephrine and related amines
Octopamine HCL 0.000222 BRL
Synephrine 0.00598 BRL
Tyramine HCL 0.00626 ND
Hordenine 0.00297 BRL
Phenylethylamine HCL 0.000316 BRL
Tryptamine 0.000343 BRL
C. aurantium aqueous leaf extract was analyzed using HPLC and GC for
limonene, rutin, naringin, naringenin, hesperidin, neohesperidin, neohesperidin
dihydrochalcone, hesperetin, nobiletin, octopamin, synephrine, tyramine, horde-
nine, phenylethylamine, and tryptamine. Only hesperidin 0.107 mg/mL, neohes-
peridin 0.0115 mg/mL, and neohesperidin dihydrochalcone 0.00125 mg/mL were
able to be quantified.
ND, Not detected above reporting limit (RL); BRL, Below reporting limit (com-
pound detected below RL).
respective to untreated animals. C. aurantium 0.5mg/mL reduced
seizure latency to 88.58% ± 11 and C. aurantium 1mg/mL to
81.4% ± 11.6 respective to untreated animals. Concentrations
above 35mg/mL caused a loss of swimming axis during absorp-
tion that extended for several minutes after transfer to PTZ. We
observed frequent occurrences of toxicity resulting in death dur-
ing the absorption period at concentrations above 35mg/mL.
For this reason, the number of animals for the concentrations of
35mg/mL and higher was kept at 5–8 animals to avoid exposing
the animals to toxic and lethal doses. We selected C. aurantium
28mg/mL for the selectivity assays because we observed the high-
est reproducible effect without constant signs of toxicity. The
increase in seizure latency to 219.4% ± 19.7, was equivalent to
a change in seizure latency from an average of 72.71% ± 3 for
naïve animals to an average of 168% ± 17.5 for animals treated
with C. aurantium 28mg/mL.
GABAA RECEPTORS ARE NOT RESPONSIBLE FOR THE EFFECT OF C.
AURANTIUM EXTRACTS
We used the GABAA receptor antagonist gabazine (GBZ) to
determine if the change in seizure latency caused by the C.
aurantium extract was caused by an interaction with GABAA
receptors (Figure 2). We used three different concentrations of
gabazine, 1.5, 3.2, and 6.4μM. Seizure latency with respect
to untreated animas after exposure to gabazine 1.5μM was
108% ± 16, for 3.2μM was 97.7% ± 17, and for 6.4μM was
59.4% ± 5. An additional concentration of 64μM was tested
as positive control for the activity of gabazine. This dose sig-
nificantly reduced seizure latency to 40% ± 6 respective to
untreated animals. Gabazine administration before exposure to
the C. aurantium 28mg/mL extract, reduced seizure latency
FIGURE 1 | Dose dependent effect of C. aurantium extract on seizure
latency to PTZ in adult zebrafish. Animals were allowed absorption on
various concentrations of C. aurantium extracts before exposure to PTZ
3mg/ml. C. aurantium extracts at 14, 20, 28, 35, and 56mg/ml, significantly
increased seizure latency compared to naïve animals. The dotted line
represents seizure latency of naïve animals. Results are shown as
average ± SEM of at least three experiments, n > 9. ∗ vs. naïve P < 0.05;
∗∗P < 0.01; ∗∗∗∗P < 0.0001.
Frontiers in Pharmacology | Ethnopharmacology February 2015 | Volume 5 | Article 284 | 4
Rosa-Falero et al. C. aurantium, zebrafish, and epilepsy
FIGURE 2 | Interaction between C. aurantium extract and GABAA
receptors. Fish were allowed 1h absorption in various concentrations of
selective GABAA receptor antagonist gabazine, followed by 1 h absorption
on C. aurantium extract at 28mg/mL prior exposure to PTZ 3mg/mL.
Gabazine alone had no significant effect when compared to the control
animals. Neither when administered before C. aurantium 28mg/mL extract.
Results are shown as average ± SEM of at least three experiments, n > 12.
∗∗ vs. Naive P < 0.01; ∗∗∗∗P < 0.0001.
to 159 ± 15% (GBZ 1.5μM), 173 ± 20% (GBZ 3.2μM), and
178.9% ± 18 (GBZ 6.4μM) respective to untreated animals.
These changes represented a reduction of 16% (GBZ 1.5μM),
7% (GBZ 3.2μM), and 4% (GBZ 6.4μM) on the effect on
seizure latency caused by the C. aurantium 28mg/mL extract
but this changes were not statistically significant, eliminating
GABAA receptors as mediators of the effect of C. aurantium
extracts.
C. AURANTIUM EXTRACT CAUSED A DOSE DEPENDENT CHANGE ON
[3H]GLUTAMATE BINDING TO GLUTAMATE RECEPTOR
We used a radioligand binding assay to determine if the C.
aurantium extract binds to glutamate receptors. Figure 3 shows
the dose dependent interaction between C. aurantium extracts
and glutamate receptors. At low concentrations (0.001, 0.003,
and 0.0056mg/mL), C. aurantium extracts significantly increased
[3H]Glu binding to glutamate receptors to 129.3% ± 4 bound,
125% ± 4.5 bound, and 130% ± 9 bound, respectively. This
represents a 26–36% increase in [3H]Glu binding to glutamate
receptors. This effect is associated to the presence of allosteric
modulators that can alter the binding affinity of the radioactive
ligand increasing on and off target binding (Leysen et al., 2014).
On the other hand, at high concentrations (0.56–5.6mg/mL), C.
aurantium extracts significantly reduced [3H]Glu binding from
67.8% ± 6 to 38.8% ± 3 bound. This represents a 30–60% reduc-
tion in [3H]Glu binding to glutamate receptors. We selected the
concentration of C. aurantium 1.4mg/mL for the In vitro interac-
tion assays because this concentration caused approximately 60%
displacement on [3H]Glu binding.
C. AURANTIUM REDUCED [3H]Glu BINDING TO NMDA AND mGluR II
We used the same radioligand binding assays in the presence
of selective glutamate receptor agonist to identify the specific
receptors C. aurantium extract binds to (Figure 4). Assay set
up included non-specific binding control (off target [3H]Glu
FIGURE 3 | Effect of C. aurantium extract on [3H]Glu binding. Synaptic
membranes were incubated with different concentrations of C. aurantium
in the presence of 20 nM [3H]Glu. C. aurantium extract reduced [3H]Glu
binding at concentrations ranging from 0.42 to 5.60mg/mL and increased
[3H]Glu binding at concentrations ranging from 0.000952 to 0.0056mg/mL.
Results are shown as percentage of total binding ± SEM of three
experiments. ∗ vs. Total P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
binding, approximately 10–20% of total binding) and total bind-
ing control to validate the selectivity of the radio-ligand (not
shown). Also, we performed controls for water, extract alone and
agonist alone to establish the baseline displacement used to com-
pare the effect of themixture of extract and agonist. Receptor ago-
nist were used at 1mM, a concentration that allows us to deter-
mine a ligand selective effect on [3H]Glu binding. C. aurantium
1.4mg/ml reduced [3H]Glu binding to 47.6% ± 2, this repre-
sent a 52% reduction in [3H]Glu binding to glutamate receptors.
Figure 4A shows ionotropic glutamate receptor (iGluR) agonist
for NMDA, AMPA (FW), and KA receptors, significantly reduced
total [3H]Glu binding to 64.2% ± 2, 81.2% ± 7, and 74.6% ±
2, respectively. These represents a 36%, 19%, and 25% reduc-
tion in [3H]Glu binding, respectively. In the presence of both,
the receptor agonist and C. aurantium extract at 1.4mg/mL, total
[3H]Glu binding was significantly reduced for NMDA receptors
to 33.7% ± 2, for AMPA receptors to 42.3% ± 3 and for Kainate
receptors to 40.4% ± 2. This represented a significant 47%
(NMDA), 48% (AMPA), and 46% (KA) reduction in [3H]Glu
binding when compared to the agonist alone. When compared to
the extract alone, it represented a significant reduction for NMDA
receptors of 29%, but not for AMPA (11% reduction) and KA
receptors, (15% reduction).
For the metabotropic glutamate receptors (mGluR)
(Figure 4B), QA (mGluR I), LCCG-I and DCG-IV (mGluR
II) and L-AP4 (mGluR III) significantly reduced total [3H]Glu
binding to 41.5% ± 2, 66.3% ± 2, 67.9% ± 2, and 68.9% ± 5.
These represented a respective 58%, 34%, 32%, and 31%
reduction in total [3H]Glu binding. When both, agonist and C.
aurantium 1.4mg/mL extracts were present, [3H]Glu binding
was significantly reduced for LCCG-I and DCG-IV and L-AP4 to
46.5% ± 2, 27.5% ± 3, and 42.6% ± 1, respectively. These repre-
sented a significant reduction in [3H]Glu binding of 30%, 60%,
and 38% when compared to the agonist alone. When compared
to the extract alone, it represented a significant reduction in
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[3H]Glu binding of 42%, but not for LCCCG-I (2% reduction)
or L-AP4 (10.6% reduction). For QA, [3H]Glu binding was
reduced to 38.1 ± 1. This represented an 8% reduction when
compared to the agonist and 19% reduction when compared to
the extract but these changes were not statistically significant.
NMDA RECEPTOR ANTAGONIST D-AP5 INHIBITS THE EFFECT OF C.
AURANTIUM ON PTZ INDUCED SEIZURES IN ZEBRAFISH
These experiments where performed using a concentration of
iGluR antagonist with no significant effect on seizure latency.
NMDA receptor antagonist D-AP5 was used at concentrations
of 2.7μM (seizure latency 66% ± 12), 6μM (seizure latency
113.4% ± 23), and 60μM (seizure latency 92.9% ± 10). Seizure
latency of the C. aurantium extract was 230.3% ± 12. Exposure
to D-AP5 2.7μM and 6μM before exposure to the C. auran-
tium 28mg/mL extract significantly reduced seizure latency to
FIGURE 4 | Selective interaction of C. aurantium extract with
glutamate receptors In vitro. Synaptic membranes were incubated with
C. aurantium extract at 1.4mg/mL in the presence of 1mM of agonists for
iGluR’s o mGluR’s and 20 nM [3H]glutamate. For these experiments,
nonspecific binding was 22% of total binding (represented with a dotted
line). All treatments significantly reduced [3H]Glu binding, when compared
with Total binding. (A) C. aurantium 1.4mg/mL reduced ligand binding in
the presence of ionotropic glutamate receptor agonist for NMDA, AMPA,
and KA receptors compared to the agonist alone. (B) C. aurantium
1.4mg/mL reduced ligand binding in the presence of metabotropic
glutamate receptor agonist for mGluR II (LCCG-I, DCG-IV) and mGluR III
(L-AP4) when compared to the agonist alone. Results are shown as
percentage of total binding ± SEM of three experiments. ++ vs. Agonist
P < 0.01; ++++P < 0.0001. ## vs. CA1.4mg/ml P < 0.01; ###P < 0.001.
157.2% ± 20 and 160.7% ± 19, respectively. This represented
a significant 32% and 30% reduction on seizure latency com-
pared to C. aurantium 28mg/mL alone (Figure 5A). Exposure
to D-AP5 60μM before exposure to the extract reduced seizure
latency to 92.8% ± 9.6 but this effect was not statistically
FIGURE 5 | Selective In vivo interaction of C. aurantium extract with
iGluR. Fish were allowed 1h absorption of various concentrations of
selective iGluR antagonist D-AP5 (NMDAR), NBQX (AMPA), UBP 301 (KAR)
followed by 1 h absorption on C. aurantium extract at 28mg/mL prior
exposure to PTZ 3mg/mL. (A) D-AP5 2.7 and 6μM prior exposures to C.
aurantium extract significantly reduced seizure latency when compared to
C. aurantium alone. (B) Exposure to NBQX prior exposures to C. aurantium
extract showed a tendency to reduce seizure latency when compared to C.
aurantium alone. (C) Exposure to UBP 301 prior exposures to C. aurantium
extract had no significant effect on seizure latency when compared to C.
aurantium alone. Results are shown as average ± SEM of at least three
experiments, n > 12. ∗∗∗∗ vs. Naive P < 0.0001, ## vs. C. aurantium
28mg/mL P < 0.01.
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significant when compared to the effect of the extract alone
(Figure 5A).
AMPA receptor antagonist NBQX was used at concentra-
tions of 1.6μM (seizure latency 94% ± 13.77), 3.5μM (seizure
latency 109% ± 25), and 35μM (seizure latency 89.7% ± 16.5).
Seizure latency of the C. aurantium extract was 214.6% ± 13.7.
Exposure to NBQX before C. aurantium had no significant effect
in seizure latency when compared to C. aurantium 28mg/mL
alone (Figure 5B) (seizure latencies 202.2%± 32.4, 195.5%± 23,
189.1% ± 25.3, respectively).
Lastly, the concentrations selected for the kainate receptor
antagonist UBP 301 were 1.2μM (seizure latency 47.8% ± 7),
2.5μM (seizure latency 50.5% ± 4), and 25μM (seizure latency
58.7% ± 6). Seizure latency of the C. aurantium extract was
246.1% ± 12. Pre exposure to UBP 301 prior exposure to C.
aurantium extracts had no effect on seizure latency when com-
pared to C. aurantium 28mg/mL alone (Figure 5C) (seizure
latencies: 249.7% ± 24, 251.4% ± 35, and 250.4% ± 14.9, respec-
tively). Since UBP 301 stock solution was prepared in DMSO
following solubility indications, DMSO controls were performed
in parallel (see Supplementary Figure 1). The corresponding con-
centrations of DMSO in the antagonist solution were 0.023%
DMSO on the UBP 301 1.2μM solution (seizure latency 95.6%±
17), 0.051% DMSO on the UBP 301 2.6μM (seizure latency
59.5% ± 7) solution and 0.51% DMSO on the UBP 301 26μM
solution (seizure latency 78.82% ± 22). DMSO alone had no sig-
nificant effect on seizure latency to PTZ, nor did it alter the effect
of C. aurantium on seizure latency (221.9% ± 0.5, 237% ± 30.2,
189.7% ± 31.7).
mGluR I ANTAGONIST PHCCC AND mGuR II ANTAGONIST EGLU
INHIBIT THE EFFECT OF C. AURANTIUM ON PTZ INDUCED SEIZURES IN
ZEBRAFISH
Figure 6 demonstrate the selectivity of the effects of C. auran-
tium extracts on seizure latency in zebrafish. These experiments
were also performed using a concentration of mGluR antago-
nist with no significant effect on seizure latency. Seizure latency
of the C. aurantium extract was 189.9% ± 13.7. We used
PHCCC at 0.5μM (seizure latency 86.1% ± 11), 1.2μM (seizure
latency 83.2% ±12.3), and 12μM (seizure latency 99.6% ±
15). Pretreatment with PHCCC (mGluR I antagonist) 0.5μM
prior exposure to C. aurantium extracts significantly reduced
seizure latency to 130.9% ± 7.8 compared to the extract alone.
This represented a 31% reduction in the effect of the C. auran-
tium 28mg/mL extract. Pretreatment with PHCCC 1.2μM prior
exposure to C. aurantium extracts increased seizure latency to
238% ± 28 but this change was not statistically significant
when compared to the effect of the extract alone. Pretreatment
with PHCCC 12μM had no significant effect on seizure latency
when compared to either the antagonist or the extract alone
(Figure 6A).
mGluR II antagonist EGLU at 3μM had a seizure latency
of 95.48% ± 10.2, at 6.4μM of 83.5% ± 13.1, and at 64μM
of 87.8% ± 13.3. Seizure latency of the C. aurantium extract
was 267.1% ± 14. Pretreatment with EGLU 3μM and 6.4μM
prior exposure to C. aurantium extract significantly reduced
seizure latency to 183.3% ± 19.4 and 194.4% ± 20.5, respectively.
FIGURE 6 | Selective In vivo interaction of C. aurantium extract with
mGluR. Fish were allowed 1h absorption of various concentrations of
selective mGluR antagonist PHCC(mGluRI), EGLU(mGluRII),
CPPG(mGLURII) followed by 1 h absorption on C. aurantium extract
28mg/mL prior exposure to PTZ 3mg/mL. (A) PHCC at 0.5μM significantly
reduced seizure latency by 32% and at 1.2μM significantly increased
seizure latency by 38% when compared to C. aurantium alone. (B) EGLU 3
and 6.4μM, significantly reduced the increase in seizure latency caused by
treatment with C. aurantium extract by 33 and 29%, respectively. (C)
mGluR III antagonist CPPG had no effect on the changes in seizure latency
caused by exposure to C. aurantium extract. Results are shown as
average ± SEM of at least three experiments, n > 12. ∗∗∗∗ vs. Naive
P < 0.0001, # vs. C. aurantium 28mg/ml P < 0.05; ##P < 0.01.
These represented a 31% (EGLU 3μM) and 27% (EGLU 6μM)
reduction in the effect of the C. aurantium 28mg/mL extract.
Pretreatment with EGLU 64μMbefore the extract had no signifi-
cant effect on seizure latency when compared to the extract alone
(seizure latency 239.8% ± 28.3).
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We used CPPG (Figure 6C), a selective mGluR III receptor
antagonist at concentrations of 2μM (seizure latency 103.2% ±
8.5), 4.3μM (seizure latency 78.6% ± 10), and 43.5μM (seizure
latency 92.1% ± 14). Pre-exposure to CPPG prior the C. auran-
tium extract had no significant effect on seizure latency when
compared to the extract alone (seizure latencies 193.9% ± 26.6,
179.1% ± 19.5, and 217.5% ± 24).
DISCUSSION
C. aurantium is extensively used as a dietary supplement for
weight loss—although efficacy has not been established. Research
on anxiolytic and anticonvulsant properties has focused on the
properties of the essential oils of the peel or the product of organic
extractions made from dried leaves (Carvalho-Freitas and Costa,
2002; Pultrini et al., 2006; Alvarado-Guzmán et al., 2009).
To our knowledge, this is the first time that an aqueous extract
made from the leaves of the C. aurantium tree has been studied,
giving insight to the pharmacological properties of a preparation
commonly used by patients, particularly in Puerto Rico. The use
of adult zebrafish to screen for activity in natural products is also
a relatively novel approach since the use of the larvae is more pop-
ular for this kind of studies and the adult is only starting to gain
popularity for this applications.
We were able to establish this aqueous preparation can increase
seizure latency to PTZ in adult zebrafish. This is consistent with
findings on mice obtained using the essential oils from the peel
of the fruit (Carvalho-Freitas and Costa, 2002). This effect was
dose dependent, and reached maximum effectiveness around
28mg/mL with higher concentrations increasing the frequency of
toxicity in the form of ataxia or loss of motor coordination caused
by neurotoxicity (Kalueff et al., 2013). We tested other members
of the citrus genus likeC. maxima (grapefruits) and from a hybrid
of C. aurantium and C. sinensis (see Supplementary Figure 2) for
anticonvulsant properties but it appears this is a unique property
of the C. aurantium tree.
We established our extract contains detectable amounts of the
flavonoids hesperidin, neohesperidin, and neohesperidin dihy-
drochalcone and trace amounts of other flavonoids like naringin,
rutin and nobiletin, and synephrine alkaloids like octopamine,
synephrine, hordenine, phenylethylamine, and tryptamine. This
is consistent with literature showing extracts from the peel of
the fruit, and the flower bloom contain similar profile of com-
pounds although we only found trace amounts of synephrine
alkaloids and these are highly abundant in this other parts of
the plant (Fugh-Berman and Myers, 2004; Liu et al., 2008).
These compounds have been attributed with a range of prop-
erties. For example, naringin is shown to cross the blood brain
barrier (Ameer et al., 1996; Zbarsky et al., 2005) and to have
antioxidant, anti-inflammatory, antihypercholesterolemic, anti-
hypertensive, neuroprotective (Golechha et al., 2011; Chanet
et al., 2012; Karimi et al., 2012), and anticonvulsant properties—it
increases seizure latency to kainic acid administration (Golechha
et al., 2011). Naringenin and hesperetin activate the peroxi-
some proliferator-activated receptor (PPAR) and up-regulating
adiponectin expression in adipocytes giving them antiathero-
genic properties (Liu et al., 2008). Hesperidin, neohesperidin,
and neohesperidin dihydrochalcone, the most abundant species
detected, are attributed antioxidant (Kumar et al., 2013; Hu et al.,
2014) anti-inflammatory (Hamdan et al., 2014; Ho and Kuo,
2014), vasopresive and antiplatelet properties (Majumdar and
Srirangam, 2009) and may be responsible for the anticonvulsant
properties of the C. aurantium extract. A broader analysis could
have revealed additional compounds present in the extract giving
a more comprehensive characterization of the extract.
It is important to understand the possible molecular mecha-
nisms behind the changes in seizure latency caused by this citrus
extract. GABA and glutamate are the mayor neurotransmitters in
the brain and are implicated in the pathophysiology of epilepsy.
We used GABAA receptor antagonist gabazine to rule out an
interaction with the GABA binding site and focused on gluta-
mate receptors. The excitatory neurotransmitter glutamate has
been implicated in early changes that lead to the initiation of
hyperactivity, but also to the amplification and spread of the exci-
tatory hyperactivity (Wong et al., 1999; Chapman, 2000;Moldrich
et al., 2003; Ure et al., 2006) acting thru two main families of
receptors, the ionotropic (iGluR) and metabotropic glutamate
receptors (mGluR)(Ozawa et al., 1998). The iGluR’s are a fam-
ily of ligand gated ion channels comprised by NMDA, AMPA,
and Kainate receptors that modulate neuronal excitability altering
ion conductance. The mGluR’s are a family of G-protein coupled
receptors comprised by subtypes 1 thru 8 that modulate cellu-
lar excitability by activation of second messenger systems and
intracellular signaling cascades. Both type of receptors have been
implicated in the etiology of different types of seizures (Bradford,
1995; Moldrich et al., 2003; Ure et al., 2006).
We used an In vitro ligand binding assay based on bind-
ing of [3H]Glu to glutamate receptors in a preparation of rat
cortical membranes to demonstrate a dose dependent inter-
action between C. aurantium extracts and glutamate recep-
tors (Figure 2). High concentrations of the extract significantly
reduced [3H]Glu binding suggesting the extract and the radio-
ligand bind and compete for the same binding site. This findings
are consistent with that observed In vivo where at high con-
centrations increased seizure latency. Low extract concentrations
significantly increased [3H]Glu binding. In ligand binding assays,
allosteric modulators can alter the binding affinity increasing the
binding of the radioactive ligand to on and off target binding
sites (Leysen et al., 2014). This suggests at this concentrations
the effect of a compound behaving as an allosteric modulator
could be prevailing and this could correlate with a slight tendency
of lower extract concentrations to reduce seizure latency. Both
observations must be studies in further detail to better under-
stand the effect of the C. aurantium extract and its interaction
with glutamate receptors.
Furthermore, we used selective receptor agonist at concen-
trations that allowed us evaluate a “ligand-selective” effect on
[3H]Glu binding to determine the selectivity of this interaction.
We identified interactions between the extract and the iGluR’s
NMDA, AMPA, and kainate receptors, and the mGluR’s groups
II and III, indicated by a significant reduction in [3H]Glu bind-
ing when C. aurantium was combined with the receptor agonists
greater than the one caused by the agonist alone. This reduc-
tion was significantly lower when compared with C. aurantium
for NMDA and DCG-IV, pointing to a stronger interactions with
Frontiers in Pharmacology | Ethnopharmacology February 2015 | Volume 5 | Article 284 | 8
Rosa-Falero et al. C. aurantium, zebrafish, and epilepsy
these two receptors. For the mGluR II, we used both DCG-IV
and LCCG-I because DCG-IV has been shown to interact with
NMDA receptors and LCCG-I is considered to be more selective
for mGluR II although it can bind to other mGluR’s at micromo-
lar concentrations (Schoepp et al., 1999; Nicoletti et al., 2011). We
saw a greater displacement of [3H]Glu binding with both DCG-
IV and LCCG-I. Interaction with multiple receptors suggest the
extract could be interacting with a common binding site in these
receptors—the glutamate binding site. Additional experiments
using radiolabeled selective agonists for each receptor could help
refine our findings.
We used our zebrafish model of PTZ induced seizures and
the C. aurantium extract at 28mg/mL to validate these inter-
actions. We selected this concentration because it gave us the
maximal protective effect with very limited toxicity events con-
trary to the higher concentrations that showed frequent toxicity.
We used selective receptor antagonists at concentrations that did
not caused a significant change in seizure latency to PTZ in the
zebrafish. NMDA receptor antagonist D-AP5 significantly reduce
the effect of C. aurantium extract on seizure latency. These sug-
gest NMDA receptors may be involved in themechanism of action
of C. aurantium. In vitro results suggest our extract might be an
antagonist at the glutamate binding site. In vivo results suggest
our extract could be acting as a receptor antagonist or as a par-
tial agonist resulting in reduced excitability because D-AP5 2.7
and 6μM suppressed the effect of the extract and with 2 recep-
tor antagonists at NMDA receptors you would expect to see an
increase of the anticonvulsant effect. According to the literature,
D-AP5 does not cross the blood brain barrier (BBB) in rodents
(Kapur and Lothman, 1990). The blood brain barrier of larvae
zebrafish is described to possess permeability properties to mam-
mals (Jeong et al., 2008) but it is not described in adult zebrafish.
Although we observed a reduction on seizure latency after expo-
sure to D-AP5, this could be due to changes in BBB permeability
caused by NMDA receptor antagonist (Neuhaus et al., 2011). To
address this, we used the noncompetitive NMDA receptor antag-
onist (MK801) that binds to the ion channel of the receptor
(Supplementary Figure 4). MK801 3.5 and 35μM significantly
increased the effect of the extract. Another mechanism that was
not evaluated could involve the glycine binding site on NMDA
receptors. AMPA receptor antagonist had no significant effect
on the seizure latency of the C. aurantium extract. KA receptor
antagonist UBP 301 alone slightly reduced seizure latency. This
reduction was not significantly different than that caused by its
DMSO vehicle suggesting this slight reduction could result from
the DMSO and not the UBP301. Despite this, the efficacy of the
extract was maintained. This should be investigated further in
order to accurately determine if KA receptors have a role in the
mechanism of C. aurantium.
For the metabotropic glutamate receptors, mGluR I antago-
nist PHCC reduced the effect of C. aurantium extracts in seizure
latency to PTZ. This receptors are associated with increased neu-
ronal excitability (reviewed by Ure et al., 2006). This could mean,
the C. aurantium extract could be acting as a receptor antago-
nist. This interaction must be evaluated in further detail since
PHCC 0.5μM significantly reduced the effect of the C. auran-
tium extract but at 1.2μM we saw a slightly increased seizure
latency over that of C. aurantium alone and 12μM slightly
reduced seizure latency. This could reflect a non-monotonic
dose response relationship for PHCC or changes in the affinity
or selectivity at the higher concentrations. Additional experi-
ments using more selective receptor antagonists including selec-
tive antagonists for receptors subtypes could help clarify this
findings.
mGluR’s II and III are associated with a reduction in neuronal
excitability (reviewed by Ure et al., 2006). mGluR II antagonist
EGLU at 3 and 6.4μM, significantly reduced the effect of the
C. aurantium extract suggesting it is acting as an agonist on this
receptors. At the higher concentration, we saw the effect of the
extract returned to its basal level suggesting at these concentra-
tions EGLU could be having of target effects. Further experiments
with subtype specific antagonist could help refine these findings.
mGluR III receptor antagonist CPPG had no effect on the increase
on seizure latency caused by the C. aurantium extract.
Taken together, these results demonstrate that the aqueous
extract made from the leaves of the C. aurantium tree possess
neuroactive properties; specifically, they alter the seizure latency
to PTZ. In addition, we demonstrated an interaction with NMDA
and mGluR’s I and II in zebrafish as predicted by pharmacologi-
cal assays. Our results suggest that C. aurantium extracts may also
be relevant to modulate affective components of behavior such as
anxiety, where mGluR’s have a crucial role in the mechanism of
the disease. In fact, preliminary experiment using the open field
test adapted for zebrafish showed anxiolytic properties (data not
shown). Also, it would be important to evaluate if this aqueous
preparation can protect against cognitive impairment, support-
ing the idea that its use as adjuvant therapy can also contribute
to reduce the sequelae caused by seizure and also some AED’s like
phenobarbital and topiramate (Cramer et al., 2010).
This result also highlight the relevance of aqueous extractions
to screen crude extracts made from natural products. We recog-
nize theses preparations pose a challenge when evaluating phar-
macokinetic and pharmacodynamic interactions but we believe
there is potential in them. Organic solvents are the most common
solvents used in the extraction of natural products. Since aqueous
and organic solvents produce extracts with different composi-
tion profile, screening them in parallel, at least at early stages
of research, could increase the success rate of the screening pro-
cess. Another important step to solidify our work would be to
repeat this experiment using the product of an organic extrac-
tion to compare the composition and effect of both preparations.
Also, our experiments were performed using only one receptor
antagonist per receptor types. Using additional selective recep-
tor antagonist and using selective antagonist for mGluR subtypes
would be important to refine our findings.
In addition, we plan to explore the anticonvulsant proper-
ties of hesperidin, the most abundant compound found in our
extract to determine if the anticonvulsant effect of the extract
could be attributed to this individual compound or if this prop-
erty results from the mixture of compounds. This would be of
great value since recent experiments show chronic oral adminis-
tration of hesperidin can reduce the course of kindling with PTZ
in mice, reduced the levels of oxidative stress indicators which
play an important role in the pathophysiology of epilepsy (Sudha
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et al., 2001; Chuang, 2010; Waldbaum and Patel, 2010; Kumar
et al., 2013).
Our results highlight the importance of naturally occurring
compounds in the treatment of epilepsy and other neurological
conditions. With our work, we expect to help draw more atten-
tion to the potential of natural product as a therapeutic options
either instead of or in combination with conventional medicine
in a not so distant future considering the use of natural products
is growing more popular (Harris et al., 2012).
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